ALK-positive T-cell lymphomas generally exhibit better responses to chemotherapy and RT compared to ALK-negative variants, likely due to the oncogenic driver role of ALK mutations that render the cells more susceptible to targeted treatments, though no clear relationship with radiation is known (156). This evidence concerns the gene ALK and T-cell non-Hodgkin lymphoma.